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ntil recently, the use of randomised controlled trials (RCTs) in surgery was notable by its absence. Research in surgical interventions was dominated by the use of historical comparative studies, case series and expert opinion. Despite representing the 'gold standard' in evidence for interventions, surgical treatments were considered too difficult for a number of reasons, including willingness of patients and surgeons to be allocated a surgical treatment by randomisation -a cornerstone of the RCT.
However, the tide is turning. There is a concerted effort by organisations such as the RCS, the National Institute for Health Research (NIHR) and medical research charities to improve use of trials in surgery, and increase training of clinicians.
ESTABLISHING THE NEED FOR AN RCT Priorities
The undertaking of an RCT is a significant investment of time and money by funders, researchers and patients. Therefore it is imperative that the trials undertaken will answer questions of genuine importance to clinicians and patients alike. Historically, deciding whether a research question was important was left solely in the hands of those in the field. However, this approach often left the most important group of people outside the room -namely the patients. To redress this imbalance, priority-setting exercises have gained an increasing role in determining where research resources should be deployed. Organisations such as the James Lind Alliance help to bring together clinicians and patients to discuss and agree strategic priorities for different health conditions. Identifying a trial that addresses one or more of these priorities provides a strong case that it should be taken forward.
Is the answer already known?
Establishing the need for an RCT is the first and one of the most important steps to be undertaken. This process is often arduous but it is an ethical and methodological imperative. Undertaking studies where the answer to the clinical question is already known or answerable is unethical and a waste of valuable resources. Funding bodies such as the NIHR will want to see exhaustive preparatory work that demonstrates a thorough and comprehensive analysis of existing relevant evidence to ensure that proceeding with a new randomised trial is the only way to answer the research question.
The most common means by which this search is undertaken is a systematic review. This is a formalised, repeatable search strategy of all available information. This is typified by the Cochrane framework, which is widely regarded as the gold standard for systematic reviews of interventions. It is good practice to write a formal protocol for the review a priori. This may be made publicly available using registries such as Prospero. The core systematic review should seek to answer the same research question that would be answered by the RCT. It may be that the studies identified do not answer the question on their own; however, when pooled together in a meta-analysis, an answer can be reached.
Local and national guidelines such as those produced by NICE also pool the existing literature and should be consulted to see if the answer to the clinical question can be found. The clinical trials registries -such as the WHO international clinical trials registry platform -should also be checked to see if a similar study is already ongoing.
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Having looked at the available data and determined that the clinical question is unanswered, one must then decide that a trial is the best and most suitable means to provide the answer.
Is an RCT going to be practical or appropriate?
There are many determinants of whether a trial is 'feasible' or practical. This may be affected by any of the working parts of the trial. It is not possible to provide an exhaustive list here as to why a study is not practical, but a common-sense checklist regarding how common the condition of interest may be, how big or small the expected effect of the intervention will be, and whether the expertise exists to deliver the intervention in the number of centres required.
Feasibility and pilot trial
One of the best ways to determine whether a trial will work is to undertake a feasibility study. As the name suggests, this is a study that seeks to determine whether a trial is feasible. These trials often recruit only a small number of patients. The study will look at willingness of patients to be recruited, the willingness of clinicians to take part, and a range of outcome measures may be used. Once the feasibility study is over, then each of these areas can be assessed and go on to inform how best to run the definitive trial. A feasibility study does not try to answer the principal research question.
Sometimes, there is much greater confidence in recruitment rate, participation and outcome measurement. In these circumstances, it may be appropriate to run a pilot trial. This is set up in exactly the same way as the definitive trial and should be thought of as a logistics exercise. Frequently, pilot trials will run continuously into the definitive trial -a so-called internal pilot.
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Sample size
The sample size calculation is a key feature of a randomised trial. It seeks to ensure enough patients are recruited to detect a difference in the outcome measure of interest at a pre-specified level of significance. The calculation takes into consideration the variability of the outcome measure, the effect expected in the study and the significance level of the statistical test that will be applied at the end of the test. The significance level is typically set at 5%; however, this may be altered according to the research question. For example, certain chemotherapeutic regimens are set at 1%. The sample size calculation is best undertaken in close collaboration with a dedicated statistician and some meaningful preliminary data. This ensures that the conclusions reached are clinically relevantthat is, relevant to patients. Each clinical trials unit will have methodologists, statisticians, health economists, programmers and administrative staff. Trials units also offer a robust framework and governance structure to ensure the trial is conducted according to the required standards.
Clinical trials units
Defining the research question
In essence, a trial is an experiment that seeks to confirm or refute a specific hypothesis. All aspects of trial design, set-up and delivery lead back to the research question. The 'PICO' framework is often a useful tool to build a research question. The research question is a sharper, clearly focused version of the clinical question. 'Should I offer operation X instead of operation Y to this patient?' might become more focused into 'Is operation X as good (or better) as operation Y in patients over 65 with disease stage A in terms of 30-day all-cause mortality?'. Each part of the research question can be considered in its component forms below.
Population
Which group of patients should take part in the trial? The results of a study that only includes a narrowly defined population will limit how 'generalisable' the studies are, ie how easily the results of the trial can be extrapolated to the whole population.
'Experimental' trial designs may use extremely precise eligibility criteria to determine the best possible outcome in highly selected patients. Whereas 'pragmatic' trial designs will give us much broader eligibility criteria to reflect better the whole population at risk. Pragmatic trials usually require much larger sample sizes.
Intervention
The intervention is usually the treatment of interest. This can be defined broadly or it can be specific. This will be determined by the clinical question. For example, a large pragmatic trial comparing a robotic with a laparoscopic surgery may only specify the approach used. By contrast, an earlier phase study may have a tightly defined intervention that specifies a particular robotic device in the hands of a specially trained surgeon.
Control arms
Deciding the comparative treatment is highly important in ensuring that a useful clinical question is answered. The most appropriate comparison is dependent on the clinical context of the trial and current clinical practice. Should the procedure of interest be compared with a different operation, non-operative treatment, no treatment at all, or a placebo operation? Each option may be suitable, depending on existing clinical practice, but in general the new treatment should be compared with the 'current best treatment option'. Of course, more than one comparator may be used in a multi-arm study. Table 1 Examples of different trials
Comparison Example
Outcomes
The metric by which each study treatment will be judged must be chosen carefully. For some studies, hard binary outcomes such as death will be most appropriate, eg in cancer trials. However, death would be a fairly useless tool to judge soft-tissue knee surgery. Studies in all healthcare fields of the past 25 years have often used a wide range of outcome measures in the same area. This heterogeneity often limits evidence synthesis, eg comparison of treatments in meta-analyses. To address this issue, the concept of a 'core outcome set' (COS) has arisen. This is a group of outcome measures that should be collected as a minimum when a particular condition is studied. Establishing a core outcome set takes into account the opinions of all stakeholders in the relevant disease area, but most importantly the patients'. An important additional consideration of the research question is whether the trial seeks to determine if a particular treatment is better (superiority) or just as good (non-inferiority or equivalence).
Registering and reporting the trial
Once a trial has been approved, the study should be recorded on an open-access trials registry.
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After the trial has recruited and the follow-up completed, investigators must report the outcome of the study. There are particular reporting guidelines that most major medical journals require. The CONSORT standard aims to identify the most important parts of a trial and to ensure that these details are available to those who wish to interpret the trial. There is an ethical obligation to report the result of a trial irrespective of its outcome; this avoids wasting resources and repetition.
GETTING INVOLVED Collaboratives
The trainee collaborative model has been shown to be effective. These groups are often focused around specialty surgical rotations and, along with a trials unit, can lead the entire trials journey. These groups provide an excellent framework for learning about trials with the support of fellow trainees and methodologists.
Courses, events and training
Local trials units often hold training on the different areas of trial conduct and analysis. There are a number of training courses run for trainees with an interest in trials, such as the Bristol Oxford Surgical Trials Course. Most hospitals offer courses in 'good clinical practice', which is often the minimum required qualification for participation in trials work. 10 The RCS also has a dedicated programme promoting the use of trials and related training. 3 This programme includes a representative surgical specialty lead (SSL) for the relevant specialty groups. Their role is to engage surgeons in developing trials and working with the RCS to launch new trials. These leads are to be supported by trainee SSLs, who will work closely with trainees to improve engagement in trials by trainees, and help with laying the groundwork for trainee-led trials.
YOUR HOSPITAL
Speak to the hospital's Research and Development department, who will be able to provide a list of the studies running in the hospital. Recruitment into a formal trial is now recognised as an alternative research outcome for surgical trainees to the two 'peer-reviewed' publications historically required by the Specialty Advisory Committee.
FURTHER READING
MRC framework on developing and evaluating complex interventions. 
